Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
24.04. | Elutia Inc.: Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1 | 1 | GlobeNewswire (USA) | ||
11.03. | ELUTIA INC. - 10-K, Annual Report | 1 | SEC Filings | ||
08.03. | Elutia Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
07.03. | Recap: Elutia Q4 Earnings | 2 | Benzinga.com | ||
07.03. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
07.03. | Elutia Inc.: Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM Clearance Decision in First Half of 2024 | 167 | GlobeNewswire (Europe) | SILVER SPRING, Md., March 07, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company") today provided a business update and reported financial results for the fourth quarter... ► Artikel lesen | |
06.03. | Preview: Elutia's Earnings | 1 | Benzinga.com | ||
22.02. | Elutia Inc.: Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024 | 2 | GlobeNewswire (USA) | ||
02.02. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
25.01. | ELUTIA INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
10.01. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
10.01. | Elutia regains compliance with Nasdaq | 1 | Seeking Alpha | ||
10.01. | Elutia Inc.: Elutia Regains Compliance with Nasdaq Listing Requirements | 199 | GlobeNewswire (Europe) | SILVER SPRING, Md., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) today announced that it has regained compliance with Nasdaq's market value of listed securities requirement and majority... ► Artikel lesen | |
27.12.23 | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
18.12.23 | Elutia submits drug-eluting biomatrix for use with cardiac implants to FDA | 2 | MassDevice | ||
08.12.23 | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
20.11.23 | Elutia files to sell 18.58M shares of Class A common stock for holders | 1 | Seeking Alpha | ||
20.11.23 | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
14.11.23 | ELUTIA INC. - 10-Q, Quarterly Report | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EPIGENOMICS | 1,570 | -3,38 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,852 | -3,84 % | Bayer auf dem Weg aus der Krise. Stehen auch Defence Therapeutics und BioNTech mit ihren Onkologie-Pipelines vor dem Turnaround? | Nach mehreren Jahren, in denen der Pharma- und Agrarchemiekonzern Bayer von einer Krise in die nächste stolperte, zeichnen sich nun Zeichen einer Erholung am Horizont ab. Während Bayer seinen langen... ► Artikel lesen | |
GINKGO BIOWORKS | 0,700 | -1,41 % | Ginkgo Bioworks Reports First Quarter 2024 Financial Results | Ginkgo announces several initiatives to accelerate path to Adjusted EBITDA breakeven by end of 2026
Initiatives include a reduction of $200 million in annualized run-rate operating expenses by mid-2025... ► Artikel lesen | |
BEAM THERAPEUTICS | 21,260 | -5,68 % | Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss | ||
RECURSION PHARMACEUTICALS | 8,600 | -0,46 % | Demystifying Recursion Pharmaceuticals: Insights From 4 Analyst Reviews | ||
ONCOLYTICS BIOTECH | 1,070 | -4,46 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports First Quarter 2024 Financial Results and Operational Highlights | Pelareorep advancing to registration-enabling studies
Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2- metastatic breast cancer
Overall survival... ► Artikel lesen | |
ASSERTIO | 0,960 | -8,57 % | Assertio Holdings, Inc.: Assertio Reports First Quarter 2024 Financial Results | First Quarter Net Product Sales of $31.9 Million Rolvedon Growth Continues, with $14.5 million in Net Product Sales $7.5 Million in Cash Flow from Operations Increases Cash to $80.7 Million... ► Artikel lesen | |
ARCTURUS THERAPEUTICS | 27,260 | +1,75 % | Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
SIGA TECHNOLOGIES | 7,460 | -3,74 % | SIGA Technologies, Inc. (SIGA) Q1 2024 Earnings Call Transcript | ||
MERRIMACK PHARMACEUTICALS | 15,120 | +0,33 % | Merrimack Pharmaceuticals stockholders approve plan of dissolution | ||
VIR BIOTECHNOLOGY | 9,440 | -1,26 % | Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings) | ||
VERVE THERAPEUTICS | 6,010 | -5,50 % | Verve Therapeutics, Inc. - 10-Q, Quarterly Report | ||
ARS PHARMACEUTICALS | 8,740 | -0,68 % | ARS Pharmaceuticals, Inc. - 8-K, Current Report | ||
BIO-PATH | 2,720 | -3,20 % | Bio-Path Holdings, Inc.: Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024 | ||
BIOMEA FUSION | 10,650 | -6,91 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |